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Abstract
Echistatin, a 5000-Da disintegrin, is a strong competitive inhibitor of platelet KIIbL3 binding to fibrinogen. In addition to
its antiplatelet activity, echistatin also exhibits activating properties by inducing a switch of KIIbL3 conformation towards an
active state. However, soluble echistatin, which is a monomeric ligand, provides only receptor affinity modulation, but it is
unable to activate integrin-dependent intracellular signals. Since proteins may exhibit a multivalent functionality as a result
of their absorption to a substrate, in this study we evaluated whether immobilised echistatin is able to stimulate platelet
adhesion and signalling. The immobilisation process led to an increase of echistatin affinity for integrin(s) expressed on
resting platelets. Unlike the soluble form, immobilised echistatin bound at comparable extent either unstimulated or ADP-
activated platelets. Furthermore, echistatin presented in this manner was effective in stimulating integrin-dependent protein
tyrosine phosphorylation. Platelets adhering to immobilised echistatin showed a pattern of total tyrosine phosphorylated
proteins resembling that of fibrinogen-attached platelets. In particular, solid-phase echistatin induced a strong
phosphorylation of tyrosine kinases pp72syk and pp125FAK. Inhibitors of platelet signalling, such as apyrase, prostaglandin
E1, cytochalasin D and bisindolylmaleimide, while not affecting platelet adhesion to immobilised echistatin, abolished
pp125FAK phosphorylation. This suggests that signals activating protein kinase C function, dense granule secretion and
cytoskeleton assembly might be involved in echistatin-induced pp125FAK phosphorylation. ß 2000 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Integrins are involved in cell adhesion and migra-
tion which occur during physiological processes such
as haemostasis, immune response, development and
in£ammation [1^4]. They are important signalling
molecules which mediate bi-directional transfer of
information from the extracellular matrix to the cy-
toplasm and vice versa [5,6].
KIIbL3, the major integrin expressed on platelet
membrane, plays a critical role in haemostasis by
mediating platelet^platelet and platelet^matrix pro-
tein interactions [1,7]. Physiological platelet agonists
activate transduction pathways (inside-out signalling)
leading to the conversion of KIIbL3 from a ‘low’ to a
‘high’ a⁄nity state, which allows the integrin to be-
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come competent to bind adhesive proteins, such as
¢brinogen and von Willebrand factor [1,8]. Follow-
ing ligand engagement, KIIbL3 triggers transduction
events (outside-in signalling) which, co-ordinated
with other signals activated by other platelet recep-
tors, lead to platelet aggregation [9].
Disintegrins are low molecular weight polypeptides
isolated from snake venoms, which are potent inhib-
itors of platelet functions [10,11]. The presence in
their molecules of the arginine, glycine, aspartic
acid (RGD) tripeptide sequence is responsible for
their antiplatelet activity, since the interaction of
KIIbL3 with its natural ligand ¢brinogen is mediated,
at least in part, through this recognition sequence
[12].
The inhibition of KIIbL3 functions by natural and
synthetic RGD-containing molecules has recently
evolved as a new antiplatelet strategy [13]. In addi-
tion to bleeding problems, a major concern related to
the use of competitive inhibitors of integrin functions
is based on their capability to induce KIIbL3 confor-
mational changes, which in turn result in an in-
creased ¢brinogen-binding function of the receptor
[14^16]. However, the switch of integrin conforma-
tion toward an activated state which can be induced
by an RGD-peptide is not su⁄cient to induce integ-
rin-dependent outside-in signalling. Integrin cluster-
ing, provided only by multivalent ligands, has been
shown to be a pre-requisite for receptor-mediated
transmembrane e¡ects [17^19]. Contortrostatin, be-
cause of its dimeric structure, is the only disintegrin
which was found to activate integrin-dependent pro-
tein phosphorylation in platelets [20].
It has been suggested that proteins may exhibit
multivalent functions as a consequence of their im-
mobilisation on a substrate [17]. As a result of this
process, a ligand may reach a high local density and
undergo conformational changes. Both these phe-
nomena may provide either a modulation of the li-
gand binding properties and/or a direct mechanism
for inducing adjacent integrin clustering [21,22].
In the present study, we show that the immobilisa-
tion on a plastic surface of echistatin, a monomeric
disintegrin from Echis carinatus venom [23], causes
an increase of its binding a⁄nity for integrin(s) ex-
pressed on resting platelets. Echistatin, when in a
solid-phase form, is also able to activate the early
phase of occupied integrin outside-in signalling, in-
cluding pp72syk phosphorylation. Furthermore, we
demonstrate that the interaction of immobilised
echistatin with platelet surfaces stimulates not only
signals dependent from integrin aggregation, but also
those transduction events required for dense granule
secretion and full platelet activation.
2. Materials and methods
2.1. Antibodies and chemicals
Rabbit polyclonal (LR), mouse monoclonal
(4D10) human pp72syk antibodies and protein A/G
PLUS-Agarose were purchased from Santa Cruz
Biotechnology, (Santa Cruz, CA, USA); rabbit poly-
clonal anti-pp125FAK serum (BC3) and anti-human
pp125FAK polyclonal IgG from Upstate Biotechnol-
ogy (Lake Placid, NY, USA); phosphotyrosine
monoclonal antibody (mAb) PT66, horseradish per-
oxidase-conjugated goat anti-mouse and anti-rabbit
IgG from Sigma (St. Louis, MO, USA); anti-KIIbL3
complex (CBL130), anti-Kv (CBL490) and anti-K5
(CBL497) antibodies from Cymbus Bioscience
(Southampton, UK); human plasma ¢brinogen (pu-
rity s 98%) and bisindolylmaleimide (BIS) from Cal-
biochem (San Diego, CA, USA); Sepharose 2B from
Pharmacia Biotech (Uppsala, Sweden); apyrase,
prostaglandin E1 (PGE1), ADP, orthovanadate, leu-
peptin, aprotinin, phenylmethylsulfonyl £uoride
(PMSF), bovine serum albumin (BSA), cytochalasin
D (CD) and indomethacin from Sigma. All the other
reagents were of the highest quality available.
2.2. Preparation of platelets
Citrated (0.32% w/v) blood specimens were ob-
tained from healthy volunteers who had not taken
any drugs for 9 days before bleeding. Platelet-rich
plasma (PRP), obtained by blood centrifugation at
200Ug for 15 min, was further centrifuged at
1200Ug for 10 min in the presence of 1 U/ml apyrase
and 1 WM PGE1. Platelets, resuspended in HEPES
bu¡er, pH 7.35, containing 137 mM NaCl, 2.7 mM
KCl, 1 mM MgCl2, 3 mM NaH2PO4, 5 mM glucose,
3.5 mM HEPES and 3.5 g/l BSA were gel-¢ltered
on Sepharose 2B [24]. The concentration of washed
platelets was assessed spectrophotometrically at
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520 nm. The platelet suspension was then diluted at
the concentration required for aggregation and adhe-
sion experiments. Platelet suspensions (2.5U108
platelets/ml), supplemented with 0.5 mg/ml ¢brino-
gen and 5 mM Ca2, were tested for their ability
to aggregate in response to 50 WM ADP. Aggrega-
tion was monitored at 37‡C on a single channel
aggregometer (Chrono-Log Aggregometer model
500-CA, Haverton, PA, USA) with continuous stir-
ring at 900 rpm. Platelets stimulated with ADP in the
absence of exogenous ¢brinogen, or platelets acti-
vated with ristocetin did not aggregate, thus indicat-
ing that the gel-¢ltration procedure yielded platelets
completely separated from plasma proteins.
2.3. Platelet adhesion assay
Gel-¢ltered unstimulated platelets were allowed to
adhere to 6 cm diameter plates (Becton-Dickinson,
NY, USA) or to 96-well polystyrene £at-bottom
plates (Costar, MA, USA) pre-coated for 16 h at
4‡C with substrates (10 Wg/ml). Echistatin was dis-
solved in 50 mM carbonate/bicarbonate bu¡er pH
9.2, whereas ¢brinogen was solubilised in phosphate
bu¡er solution (PBS). Unbound sites on the plastic
were blocked with 2 ml/plate or 200 Wl/well of 5 mg/ml
heat-denatured BSA for 1 h at 37‡C. Wells coated
with BSA were used to check aspeci¢c platelet adhe-
sion. After three washing with PBS, plates were ¢lled
with 50 Wl of a platelet suspension (3U108/ml) sup-
plemented with 1 mM CaCl2 and left for 1 h at room
temperature. Non-adherent platelets were removed
and the plates were washed twice with PBS. Quanti-
tative evaluation of the number of adherent platelets
was performed in microtitre wells by measuring
platelet endogenous phosphatase [25]. The plates
were read at 410/630 nm on an automated plate
reader (Bio-Rad model 450, Hercules, CA, USA).
Platelet pre-treatments with inhibitors of platelet ac-
tivation were performed as it follows: (1) 10 min
with 10 U/ml apyrase or 12 nmol/ml CD or
10 nmol/ml indomethacin; (2) 1 min with 1 nmol/ml
PGE1 ; 1 h with 12 nmol/ml BIS. The anti-ag-
gregatory activity of these inhibitors was tested be-
fore their use. Adhesion experiments were also
performed by adding to the platelet suspension a
mixture of protease inhibitors (20 Wg/ml leupeptin,
100 U/ml aprotinin, and 100 WM PMSF) or hirudin
(20 U/ml). In an other set of experiments, platelets
were pre-incubated for 5 min with 10 Wg/ml anti-
KIIbL3 alone or 5 min with anti-KIIbL3 plus further
5 min with anti-Kv or anti-K5 antibodies.
2.4. Protein immunoprecipitation and Western
blotting
Adherent platelets were lysed with 600 Wl of ice
cold RIPA bu¡er, containing 1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS, 158 mM NaCl,
10 mM Tris^HCl, pH 7.2, 1 mM EGTA, 1 mM
PMSF, 20 Wg/ml leupeptin, 100 U/ml aprotinin,
and 1 mM sodium orthovanadate. Platelets in sus-
pension were lysed by adding an equal volume of
2URIPA bu¡er. After 30 min on ice, lysates were
clari¢ed by centrifugation at 14 000 rpm for 10 min
at +4‡C. The resulting supernatants were character-
ised for protein concentration by Bio-Rad DC pro-
tein assay. Equal amounts of proteins were immuno-
precipitated overnight at 4‡C with anti-pp125FAK
(BC3) (1 Wg/100 Wg proteins) or anti-pp72syk (LR)
(3 Wl of a 1:5 antibody dilution/100 Wg proteins)
previously bound to protein A/G-Agarose. Beads
were sedimented by brief centrifugation and washed
extensively with ice-cold RIPA bu¡er. Proteins, solu-
bilised in boiling SDS sample bu¡er (2% SDS, 5%
L-mercaptoethanol, 66 mM Tris, pH 7.5, 10 mM
EDTA), were separated on a 10% SDS-polyacryl-
amide gel and transferred to nitrocellulose. Western
blotting analyses were performed as previously de-
scribed [26]. To evaluate protein tyrosine phosphor-
ylation, blots were probed with mAb PT66
(1:10 000). To monitor the loading of gel lanes, the
membranes were stripped according to the Manufac-
turer’s procedure (Amersham, Buckinghamshire,
UK) and then reprobed with the anti-human
pp125FAK (1:500) or anti-pp72syk (4D10) (1:200)
antibodies. Immunoreactive bands were visualised
by enhanced chemiluminescence kit (Amersham).
Quantitisation of proteins was performed by densi-
tometry using a Discover Pharmacia scanner
equipped with a sun spark classic densitometric
workstation.
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3. Results
3.1. Platelet adhesion to immobilised echistatin
Gel-¢ltered human platelets showed the capability
to adhere to immobilised ¢brinogen and echistatin
(Fig. 1), whereas they attached to BSA-coated wells
only at a very low extent. The number of adherent
platelets was shown to be a function of both the
amount of coating disintegrin (Fig. 1A) and the con-
centration of the poured platelet suspension (Fig.
1B). The percentage of platelets attached to ¢brino-
gen- or echistatin-coated wells was about 20 and
17%, respectively, when 0.5 Wg of protein was immo-
bilised on plates. A similar percentage of human
platelet adhesion to immobilised ¢brinogen has
been previously reported [25]. When the adhesion
experiments were performed with washed platelets
resuspended in EDTA-supplemented HEPES bu¡er,
platelets did not attach to immobilised echistatin,
thus indicating that platelet binding to immobilised
echistatin requires the presence of Ca2 (data not
shown). Platelet exposure to 0.1 WM echistatin for
3 min before plating completely inhibited their adhe-
sion to echistatin- and ¢brinogen-coated wells (Fig.
1B, dotted lines). This indicates that the same integ-
rin sequences are recognised by both soluble and
immobilised echistatin.
Soluble echistatin has been previously reported to
bind with higher a⁄nity to stimulated platelets than
to resting-ones [27]. Immobilised echistatin was
found to support at comparable extent the adhesion
of either unstimulated or ADP-activated platelets
(Fig. 1A). To rule out that a partial platelet activa-
tion, which may occur during platelet collection and
isolation, was responsible for the di¡erent a⁄nity
Fig. 1. Platelet adhesion to immobilised echistatin. Unstimulated (a) and ADP-activated (b) platelets (1.5U107) were poured on wells
coated with increasing amounts of echistatin (A). Di¡erent numbers of unstimulated platelets (solid line) or platelets previously treated
with 0.1 WM of soluble echistatin for 3 min (dotted line) were poured on wells coated with 0.5 Wg/well echistatin (E) or ¢brinogen (F)
(B). The plates were incubated at room temperature for 1 h. Non-adherent platelets were removed and the number of adherent plate-
lets was measured as described in Section 2. The number of platelets adhering to BSA-coated wells has been subtracted from the num-
ber of platelets adhering to echistatin- or ¢brinogen-coated wells. The results reported here are the mean values from three di¡erent
experiments in which each point was tested 10-fold. Standard deviations never exceeded 10% of the mean value.
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properties of the two forms of echistatin, adhesion
experiments were performed in the presence of the
aggregation inhibitors PGE1 and apyrase. None of
these inhibitors was e¡ective in reducing the number
of platelets adhering to immobilised echistatin and
¢brinogen (Table 1). The possibility that platelet ac-
tivation might occur because of plasmin or thrombin
traces present in the platelet preparation, was also
ruled out, since the extent of platelet adhesion to
immobilised echistatin was unchanged by protease
inhibitors (PMSF, leupeptin, aprotinin) or by hirudin
(Table 1).
Previous ¢ndings showed that the blockade of spe-
ci¢c platelet transduction pathways does not a¡ect
platelet binding to solid-phase ¢brinogen [21,28].
Likewise, platelets pre-treated with CD, an inhibitor
of actin polymerisation, or BIS, a protein kinase C
(PKC) inhibitor, or indomethacin, an inhibitor of
arachidonate metabolism, adhered to echistatin-
coated wells as well as control platelets (Table 1).
These results indicate that platelet adhesion to im-
mobilised echistatin does not require platelet activa-
tion by agonists and does not involve platelet signal-
ling.
Immobilised echistatin-platelet interaction is
mainly mediated by KIIbL3 integrin. In fact, platelet
adhesion to immobilised echistatin was reduced by
Table 1
E¡ect of inhibitors on platelet adhesion to immobilised echista-
tin or ¢brinogen
Inhibitor Number of adherent-platelets
(U106/well)
Echistatin Fibrinogen
None 2.71 þ 0.26 3.02 þ 0.28
PGE1 2.65 þ 0.25 3.10 þ 0.25
Apyrase 2.52 þ 0.24 3.05 þ 0.27
Indomethacin 2.60 þ 0.26 3.10 þ 0.26
CD 2.73 þ 0.24 2.91 þ 0.28
BIS 2.80 þ 0.23 2.95 þ 0.29
Aprotinin, leupeptin, PMSF 2.55 þ 0.24 3.03 þ 0.27
Hirudin 2.61 þ 0.25 2.90 þ 0.28
Gel-¢ltered platelets were treated with di¡erent platelet inhibi-
tors at concentrations and for the incubation time reported in
Section 2. Platelets were allowed to adhere to echistatin- or ¢-
brinogen-coated wells (0.5 Wg/well). The plates were incubated
at room temperature for 1 h. Non-adherent platelets were re-
moved and the number of adherent platelets was assessed as de-
scribed in Section 2. The number of platelets adhering to BSA-
coated wells (0.31U106 þ 0.02) has been subtracted from the
number of platelets adhering to immobilised echistatin or ¢brin-
ogen. Data are the mean values þ S.D. calculated from three
separate experiments in which each point was tested 10-fold.
Fig. 2. Protein tyrosine phosphorylation in platelets adhering to immobilised echistatin or ¢brinogen. Lysates containing equal
amounts of proteins from platelets adhering to immobilised ¢brinogen (lane 1), immobilised echistatin (lane 2) or BSA (lane 3) or
lysed platelets taken in suspension for 3 min in the presence of 0.1 WM soluble echistatin (lane 4) were either directly run on SDS^
PAGE (A) or immuno-precipitated with pp72syk (LR) antibody (B) or pp125FAK (BC3) antibody (C) and subsequently separated by
electrophoresis. After Western blotting, tyrosine phosphorylated proteins were visualised by mAb PT66. The amount of pp72syk or
pp125FAK loaded was equal in all lanes of each gel as it was veri¢ed on parallel immunoblots probed with the anti-pp72syk antibody
(4D10) (B, lower blot) or with the polyclonal anti-human pp125FAK antibody (C, lower blot). The position of molecular markers (in
kDa) and of pp72syk or pp125FAK (arrows) is indicated. The same results were obtained from three separate experiments of equal de-
sign.
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83% in the presence of anti-KIIbL3 antibody. How-
ever, the integrin receptors KvL3 and K5L1 could
also be involved in such interaction, since a statisti-
cally signi¢cant higher inhibition of platelet adhesion
to immobilised echistatin was observed when plate-
lets were simultaneously treated with anti-KIIbL3 plus
anti-Kv or anti-K5 antibodies (data not shown).
3.2. Platelet adhesion to immobilised echistatin
promotes protein tyrosine phosphorylation
Several tyrosine phosphorylated proteins resulted
as a consequence of platelet binding to the natural
ligand ¢brinogen or to immobilised echistatin (Fig.
2A). The pattern of phosphorylated proteins in echi-
statin-attached platelets resembled that of ¢brinogen-
adherent platelets. Platelets held in suspension or
platelets attached to BSA showed very low levels of
total protein phosphorylation, thus indicating that
platelet signalling was speci¢cally dependent upon
platelet adhesion to immobilised ¢brinogen or echi-
statin.
Lysates containing equal amount of proteins, from
echistatin-, ¢brinogen- and BSA-adherent platelets,
were assayed for the tyrosine phosphorylation of
pp72syk and pp125FAK, two kinases activated at
di¡erent levels downstream integrin^ligand engage-
ment. pp72syk resulted strongly phosphorylated in
echistatin-attached platelets as well as in platelets
adhering to ¢brinogen (Fig. 2B). pp72syk phosphor-
ylation was observed, even though at a low extent,
also in platelets adhering to BSA. This result is
not surprising, as previous studies demonstrated
that resting platelets exhibit a basal level of pro-
tein tyrosine phosphorylation, including pp72syk
[29].
Immobilised echistatin-platelet interaction induced
pp125FAK phosphorylation and the level of phos-
phorylation was comparable to that measured in
¢brinogen-adherent platelets (Fig. 2C). Unlike
pp72syk, phosphorylated pp125FAK was completely
absent in platelets adhering to BSA. Thus, we can
rule out that a partial platelet activation, due to the
presence of Ca2 ions in the adhesion bu¡er, might
be responsible for the activation of this kinase in
echistatin- or ¢brinogen-attached platelets. The lack
of any protein tyrosine phosphorylation in sus-
pended platelets exposed to soluble echistatin (Fig.
2, lane 4) con¢rmed that pp72syk and pp125FAK acti-
vating signals arise only as a consequence of the
binding of platelets with the solid-phase form of
the disintegrin. Preliminary experiments by light mi-
Fig. 3. E¡ect of inhibitors on pp125FAK phosphorylation induced by platelet adhesion to immobilised echistatin or ¢brinogen.
pp125FAK phosphorylation was measured in platelets allowed to adhere to plates coated with echistatin (A) or ¢brinogen (B) in the
absence (lane 1) and in the presence of apyrase (lane 2), PGE1 (lane 3), indomethacin (lane 4) and cytochalasin D (lane 5). C shows
the results obtained from control platelets left for 1 h at room temperature (lanes 1 and 3) and BIS-pre-treated platelets (lanes 2 and
4) adhering to echistatin (lanes 1 and 2) or ¢brinogen (lanes 3 and 4). Platelet lysates containing equal amounts of proteins were sub-
jected to immunoprecipitation with anti-pp125FAK (BC3) antibody and subsequently separated by electrophoresis. Tyrosine phosphory-
lated proteins were visualised by mAb PT66 (upper blots). The blots were stripped and reprobed with polyclonal anti-human
pp125FAK antibody (lower blots). The position of molecular markers (in kDa) and pp125FAK (arrow) is indicated. Similar results were
obtained from four experiments of identical design.
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croscopy analysis of paraformaldehyde-¢xed platelets
showed that platelets adhering to immobilised ¢-
brinogen or echistatin, where pp125FAK resulted
phosphorylated, also spread. Conversely, platelets at-
tached to the substrates in the presence of apyrase,
which prevented pp125FAK phosphorylation, did not
spread (data not shown). These ¢ndings are in agree-
ment with previously reported data [30^31].
The involvement of speci¢c transduction pathways
in the echistatin-induced pp125FAK phosphorylation
was investigated by using inhibitors of platelet sig-
nalling. Platelets were pre-treated with PGE1, apyr-
ase, indomethacin, CD, or BIS before plating.
pp125FAK phosphorylation was completely abolished
by all, but one, of used inhibitors (Fig. 3). In partic-
ular, PGE1, apyrase, CD and BIS were shown to be
e¡ective, thus indicating that signals activating and/
or depending on dense granule secretion, cytoskele-
ton assembly and PKC function are involved in
echistatin-induced pp125FAK phosphorylation. The
presence of phosphorylated pp125FAK in control
platelets left for 1 h at room temperature (Fig. 3C,
lane 3) con¢rms that the lack of pp125FAK phosphor-
ylation in BIS-pre-treated platelets was due to the
inhibition of PKC and not to an aspeci¢c impair-
ment of platelet functions caused by the long plate-
let-inhibitor pre-incubation time. Indomethacin,
which is known to inhibit the cyclooxygenase path-
way, did not cause any reduction of echistatin-in-
duced pp125FAK phosphorylation (Fig. 3A, lane 4).
The e¡ects of platelet inhibitors on pp125FAK activa-
tion triggered by platelet adhesion to ¢brinogen (Fig.
3B) are in agreement with data previously reported
by Haimovich et al. [28].
4. Discussion
Echistatin is a potent inhibitor of platelet aggrega-
tion stimulated by various agonists [23,32]. It binds
with high a⁄nity to the puri¢ed platelet receptor
KIIbL3 : the cross-linking of the disintegrin occurs
within the L3 217^302 sequence, a domain which
has been implicated in many receptor functions,
such as heterodimer association, activation-depen-
dent conformational changes and ¢brinogen binding
[33,34]. We have recently demonstrated that soluble
echistatin inhibits pp72syk and pp125FAK phosphory-
lation in ADP-stimulated ¢brinogen-adherent plate-
lets [26].
In order to gain more insights into the mechanism
of action of disintegrins on platelet functions, in this
study we investigated the capability of immobilised
echistatin to support platelet adhesion and signalling
activation.
Gel-¢ltered human platelets attach to echistatin-
coated plates, as a function of both the disintegrin
coating concentration and the number of plated
platelets (Fig. 1). While the binding a⁄nity of soluble
echistatin to resting platelets was found to be much
lower than its binding a⁄nity to ADP-activated
platelets [27], the number of platelets adhering to
immobilised echistatin in the absence of ADP is al-
most comparable to that measured in the presence of
the agonist. Such a di¡erence in the receptor binding
a⁄nity of di¡erent forms (soluble or solid-phase) of
the same molecule has been already observed, includ-
ing for the platelet natural ligand ¢brinogen [21,34].
New binding properties can be acquired by these
molecules as a consequence of immobilisation-in-
duced conformational changes [17]. Echistatin coat-
ing on a plastic surface may allow its RGD loop and
the C-terminal secondary binding sequence to be-
come more accessible for KIIbL3 expressed on unstim-
ulated platelets. This might be particularly true for
the echistatin positively charged.
C-terminal domain, which has been shown to be
responsible for echistatin-induced ligand induced
binding sites (LIBS) expression on puri¢ed KIIbL3
[35,36].
The interaction between echistatin and platelet re-
ceptor KIIbL3 and the subsequent activation of the
receptor do not require transduction signals induced
by agonists. In fact, the level of platelet adhesion to
immobilised echistatin is not a¡ected by the presence
of inhibitors of platelet signalling and aggregation
(Table 1).
Monomeric disintegrins and other RGD mimetics,
which are able to modulate integrin a⁄nity, fail to
activate signals mediated by these receptors [15,16].
Only the disul¢de-linked dimeric disintegrin contor-
trostatin was shown to activate the early phase of
KIIbL3 outside-in signalling [20]. This ¢nding and ana-
logue results obtained with antibody-induced integrin
crosslink [37] led to the conclusion that receptor oli-
gomerisation is a condition necessary to initiate bio-
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chemical signals. Here, we show that platelet inter-
action with immobilised echistatin promotes the
phosphorylation of pp72syk, a kinase involved in
the early phase of clustered-integrin signalling (Fig.
2). This indicates that echistatin, when occurs in a
solid-phase form, exerts the function of a multivalent
ligand, allowing adjacent integrin aggregation, and
thus exhibiting properties similar to those of contor-
trostatin. However, unlike this dimeric disintegrin,
echistatin in adherent platelets activates also the ty-
rosine phosphorylation of the focal adhesion kinase,
pp125FAK (Fig. 2), which is regulated in a pattern
distinct from that of pp72syk [38]. Previously, it has
been found that clustering of KIIbL3 mediated by
antibodies, which recognise the activate form of the
receptor, failed to trigger pp125FAK phosphorylation
[39]. Thus, the presence of phosphorylated pp125FAK
in platelets adhering to immobilised echistatin sug-
gests that the disintegrin binds and clusters the rest-
ing form of KIIbL3. Furthermore, inhibition experi-
ments show that immobilised echistatin activates
signals resembling those induced by solid-phase ¢-
brinogen (Fig. 3), which is known to cluster the
non-active form of KIIbL3 [39]. In platelets adhering
to ¢brinogen, the activation of pp125FAK requires
both signals induced by the occupied integrin and
signals activated by ADP secreted from platelet
dense granules [31]. We found that, in platelets at-
tached to immobilised echistatin, the phosphory-
lation of pp125FAK is completely abolished by the
addition of apyrase, an ADP scavenger, and PGE1,
an inhibitor of secretion (Fig. 3). This indicates that
immobilised echistatin, like immobilised ¢brinogen,
also stimulates signals responsible for endogenous
agonist secretion. Further similarities between immo-
bilised echistatin- and ¢brinogen-activated transduc-
tion pathways are observed by using other inhibitors
of intraplatelet signals (Fig. 3). For both substrates,
the cytoskeleton integrity and PKC functionality are
conditions necessary for pp125FAK phosphorylation,
whereas the e⁄ciency of cycloxygenase pathway is
not required.
Adhesion experiments performed in the presence
of anti-KIIbL3, without or with anti-Kv or anti-K5 sub-
units, show that KIIbL3 is the main receptor involved
in immobilised echistatin-platelet interaction. Even
though echistatin has been shown to bind KvL3 and
K5L1 receptors with higher a⁄nity than KIIbL3 [40],
KIIbL3 is a thousand-fold more abundant than KvL3
and K5L1 on platelet surfaces. Furthermore, the ob-
served similarities between signal transduction path-
ways stimulated by solid-phase echistatin and those
activated by KIIbL3-immobilised ¢brinogen strongly
suggest that KIIbL3 is the integrin responsible for sig-
nals arising in echistatin-adherent platelets. However,
KvL3 and K5L1 which can be activated by ligand-
mimetic binding [16,41], may play a role in echista-
tin-induced pp125FAK phosphorylation, since the ac-
tivation of this kinase is a general property of L3 and
L1 subunit signalling [42]. Furthermore, KvL3 and
K5L1 may contribute to echistatin-induced signalling
by activating KIIbL3, according to recent ¢ndings
which demonstrate that an integrin can modulate
positively or negatively the function of an other in-
tegrin [43,44]. Studies are in progress to clarify
whether and how KvL3 and K5L1 participate to sig-
nals in echistatin-adherent platelets.
Previous studies demonstrating the integrin acti-
vating property of disintegrins and other RGD-li-
gand mimetics [14,15], raise the question whether
these compounds promote rather than prevent
thrombus formation. In fact, they, inducing KIIbL3
high a⁄nity state, may allow ¢brinogen-dependent
aggregation without the need of agonists [14]. In ad-
dition to the property to modulate integrin a⁄nity,
our results highlight that the RGD polypeptide echi-
statin, when occurring in a solid-phase form, also in-
duces complex transduction events which may result
in full platelet activation. Our model of solid-phase
echistatin may mimic an event which might also oc-
cur in the blood environment with integrin antago-
nist drugs. In fact, these chemicals may be associated
to platelets for a relatively long time as a result of
their interaction with KIIbL3 [45], thus acquiring the
properties of an immobilised substrate for other cir-
culating cells and thus promoting their activation.
In conclusion, our ¢ndings suggest that a better
understanding and further characterisation of the po-
tential activating properties of RGD antagonists is
crucial for the future development of anti-thrombotic
drugs based on integrin blockade therapeutic strat-
egies.
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